Your browser is no longer supported. Please, upgrade your browser.
LOXO Loxo Oncology, Inc. daily Stock Chart
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-2.09 Insider Own4.12% Shs Outstand30.75M Perf Week-
Market Cap- Forward P/E- EPS next Y-3.38 Insider Trans0.00% Shs Float27.36M Perf Month-
Income- PEG- EPS next Q-0.81 Inst Own99.70% Short Float3.75% Perf Quarter-
Sales144.80M P/S- EPS this Y59.30% Inst Trans- Short Ratio- Perf Half Y-
Book/sh12.41 P/B- EPS next Y-56.50% ROA- Target Price225.00 Perf Year-
Cash/sh- P/C- EPS next 5Y37.00% ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees59 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility- -
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom2.40 SMA20- SMA50- SMA200- Volume0 Change-
Jul-29-19 08:50AM  Stock market news: July 29, 2019 Yahoo Finance
Apr-17-19 10:14AM  Double Top Spells Trouble for 3 Health Care Stocks Investopedia
Mar-14-19 01:13PM  Steven Cohen Takes Stake in Aptevo Therapeutics
Feb-20-19 10:13AM  Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook Moody's
Feb-19-19 08:00AM  Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-15-19 04:10PM  Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company Moody's
11:43AM  Bayer gains full Vitrakvi rights from Eli Lilly's Loxo Reuters
09:23AM  Lilly Completes Acquisition of Loxo Oncology PR Newswire
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-07-19 07:31AM  5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure Motley Fool
Feb-06-19 04:33PM  Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal
03:04PM  Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript Motley Fool
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.